Avalanche Biotechnologies, Inc.
SEC CIK 1501756 · [AAVL] · last insider filing 2025-12-10
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Whitcup Scott M | Director | filed 2020 - 2025 |
| Machado Patrick | Director | filed 2017 - 2025 |
| Scopa James Paul | Director | filed 2019 - 2025 |
| Fischer Laurent | Director · CEO, President and Director | filed 2020 - 2025 |
| Tuckson Reed Vaughn | Director | filed 2021 - 2025 |
| Svoronos Dawn | Director | filed 2020 - 2025 |
| Nicholson, C. David | Director | filed 2023 - 2025 |
| Lupher, Jr. Mark L. | Director | filed 2019 - 2025 |
| Ozden Rabia Gurses | Director · Chief Medical Officer | filed 2022 - 2025 |
| Hong Soo | Director | filed 2022 - 2025 |
| Kiss Szilard | Director | filed 2024 - 2025 |
| Gasmi Mehdi | Director · VP, Pharmaceutical Development | filed 2014 - 2021 |
| Woiwode Thomas | Director | filed 2016 - 2021 |
| Patterson Leone D | Director · SVP, CFO, Interim Pres and CEO | filed 2016 - 2021 |
| Carter Eric G | Director | filed 2017 - 2020 |
| Hemrajani Rekha | Director | filed 2019 - 2020 |
| Finer Mitchell H. | Director | filed 2016 - 2019 |
| Spivey Richard N. | Director | filed 2017 - 2019 |
| Cleveland Paul B | Director · President and CEO | filed 2015 - 2018 |
| Salzman Amber | Director · President and COO | filed 2016 - 2018 |
| Schwartz Steven Daniel | Director | filed 2014 - 2017 |
| Wachter Paul | Director | filed 2014 - 2016 |
| Mclaughlin John Peter | Director | filed 2014 - 2016 |
| Blumenkranz Mark S. | Director | filed 2014 - 2016 |
| Chalberg Thomas W. | Director · Chief Executive Officer | filed 2014 - 2015 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Rubinstein Linda M | Chief Financial Officer | filed 2022 - 2025 |
| Soparkar Peter | See Remarks section | filed 2019 - 2025 |
| Seyedkazemi Setareh | Chief Development Officer | filed 2022 - 2025 |
| Riley Brigit | Chief Scientific Officer | filed 2021 - 2023 |
| Beckman Richard | Chief Medical Officer | filed 2022 - 2023 |
| Rakow John | SVP, Genl Counsel, Acting CFO | filed 2022 - 2022 |
| Pecota Nancy E | Principal Accounting Officer | filed 2022 - 2022 |
| D'Souza Rupert | Chief Financial Officer | filed 2021 - 2022 |
| Clark Julie | Chief Medical Officer | filed 2021 - 2021 |
| Thrift Jack Anthony | Interim CFO | filed 2021 - 2021 |
| Thedinga Angela | Chief Technology Officer | filed 2020 - 2021 |
| Derespino Christopher | See Remarks | filed 2021 - 2021 |
| Osborne Aaron | Chief Medical Officer | filed 2019 - 2021 |
| Leung Thomas | Chief Financial Officer | filed 2019 - 2020 |
| Cheng Jennifer C. | General Counsel | filed 2017 - 2019 |
| Countouriotis Athena | SVP, Chief Medical Officer | filed 2017 - 2018 |
| Barone Samuel B. | SVP, Clinical Development | filed 2014 - 2017 |
| Russo Carlo | EVP and Chief Medical Officer | filed 2016 - 2016 |
| Rubio Roman G. | SVP, Translational Medicine | filed 2014 - 2016 |
| Braun Shirley | VP, Human Resources | filed 2015 - 2016 |
| Swartzburg Michael | VP, Finance and Controller | filed 2015 - 2016 |
| Bain Linda | Chief Financial Officer | filed 2014 - 2015 |
| Hull Hans | SVP, Legal and Corp. Dev. | filed 2014 - 2015 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.